The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors
Open accessAbstract
An effective combination immunotherapy using oncolytic viruses delivers de novo CD19 to promote CD19-CAR T cell therapy against solid tumors in mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
O’Rourke, D. M., Nasrallah, M. P., Desai, A., Melenhorst, J. J., Mansfield, K., Morrissette, J. J. D., Martinez-Lage, M., Brem, S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,803
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
Gust, J., Hay, K. A., Hanafi, L.-A., Li, D., Myerson, D., Gonzalez-Cuyar, L. F., Yeung, C., Liles, W. C., Wurfel, M., Lopez, J. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0698 · Cited by 1,400
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,286
Hay, K. A., Hanafi, L.-A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M., López, J. A., Chen, J., Chung, D., Harju-Baker, S., et al. (2017) · Blood · doi:10.1182/blood-2017-06-793141 · Cited by 1,156
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Crowe, A., & Yue, W. (2019) · BIO-PROTOCOL · doi:10.21769/bioprotoc.3465 · Cited by 771
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Maude, S. L., Teachey, D. T., Porter, D. L., & Grupp, S. A. (2015) · Blood · doi:10.1182/blood-2014-12-580068 · Cited by 727
Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711
Integrating oncolytic viruses in combination cancer immunotherapy
Bommareddy, P. K., Shettigar, M., & Kaufman, H. L. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0014-6 · Cited by 704
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
Breitbach, C. J., Burke, J., Jonker, D., Stephenson, J., Haas, A. R., Chow, L. Q. M., Nieva, J., Hwang, T.-H., Moon, A., Patt, R., et al. (2011) · Nature · doi:10.1038/nature10358 · Cited by 551
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
Koneru, M., Purdon, T. J., Spriggs, D., Koneru, S., & Brentjens, R. J. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.994446 · Cited by 418
Oncolytic viruses as engineering platforms for combination immunotherapy
Twumasi-Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C., & Nelson, B. H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0009-4 · Cited by 417
Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Blood · doi:10.1182/blood-2010-01-265041 · Cited by 391
Rehman, H., Silk, A. W., Kane, M. P., & Kaufman, H. L. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0158-5 · Cited by 362
Her-2 Overexpression Increases the Metastatic Outgrowth of Breast Cancer Cells in the Brain
Palmieri, D., Bronder, J. L., Herring, J. M., Yoneda, T., Weil, R. J., Stark, A. M., Kurek, R., Vega-Valle, E., Feigenbaum, L., Halverson, D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3316 · Cited by 333
Nishio, N., Diaconu, I., Liu, H., Cerullo, V., Caruana, I., Hoyos, V., Bouchier-Hayes, L., Savoldo, B., & Dotti, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0697 · Cited by 331
Wang, X., Popplewell, L. L., Wagner, J. R., Naranjo, A., Blanchard, M. S., Mott, M. R., Norris, A. P., Wong, C. W., Urak, R. Z., Chang, W.-C., et al. (2016) · Blood · doi:10.1182/blood-2015-12-686725 · Cited by 322
Self-citationCellular and Humoral Immunity against Vaccinia Virus Infection of Mice
Xu, R., Johnson, A. J., Liggitt, D., & Bevan, M. J. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.6265 · Cited by 260
Wing, A., Fajardo, C. A., Posey, A. D., Shaw, C., Da, T., Young, R. M., Alemany, R., June, C. H., & Guedan, S. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0314 · Cited by 252
Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection
Kumaresan, P. R., Manuri, P. R., Albert, N. D., Maiti, S., Singh, H., Mi, T., Roszik, J., Rabinovich, B., Olivares, S., Krishnamurthy, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312789111 · Cited by 237
Making CAR T Cells a Solid Option for Solid Tumors
Schmidts, A., & Maus, M. V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02593 · Cited by 187
Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds
Sivanandam, V., LaRocca, C. J., Chen, N. G., Fong, Y., & Warner, S. G. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.04.003 · Cited by 176
Self-citationChekmasova, A. A., Rao, T. D., Nikhamin, Y., Park, K. J., Levine, D. A., Spriggs, D. R., & Brentjens, R. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0192 · Cited by 171
Priceman, S. J., Gerdts, E. A., Tilakawardane, D., Kennewick, K. T., Murad, J. P., Park, A. K., Jeang, B., Yamaguchi, Y., Yang, X., Urak, R., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1380764 · Cited by 166
Self-citationOncolytic Virus Combination Therapy: Killing One Bird with Two Stones
Martin, N. T., & Bell, J. C. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.04.001 · Cited by 160
Cripe, T. P., Ngo, M. C., Geller, J. I., Louis, C. U., Currier, M. A., Racadio, J. M., Towbin, A. J., Rooney, C. M., Pelusio, A., Moon, A., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.243 · Cited by 159
Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers
Downs‐Canner, S., Guo, Z. S., Ravindranathan, R., Breitbach, C. J., O’Malley, M. E., Jones, H. L., Moon, A., McCart, J. A., Shuai, Y., Zeh, H. J., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.101 · Cited by 146
Murad, J. P., Kozłowska, A. K., Lee, H. J., Ramamurthy, M., Chang, W.-C., Yazaki, P. J., Colcher, D. M., Shively, J. E., Cristea, M. C., Forman, S. J., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02268 · Cited by 145
Self-citationYang, H., Kim, S.-K., Kim, M., Reche, P. A., Morehead, T. J., Damon, I. K., Welsh, R. M., & Reinherz, E. L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523220 · Cited by 139
Self-citationReview: Oncolytic virotherapy, updates and future directions
Fountzilas, C. K., Arora, S. P., & Mahalingam, D. (2017) · Oncotarget · doi:10.18632/oncotarget.18309 · Cited by 138
Prospects for combined use of oncolytic viruses and CAR T-cells
Ajina, A., & Maher, J. F. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0294-6 · Cited by 121
Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis
Lauer, U. M., Schell, M., Beil, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0244 · Cited by 116
Breitbach, C. J., Moon, A., Burke, J., Hwang, T.-H., & Kirn, D. H. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2727-2_19 · Cited by 92
Biology and clinical application of CAR T cells for B cell malignancies
Davila, M. L., & Sadelain, M. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2039-6 · Cited by 91
Liu, Y., Chen, X., Han, W., & Zhang, Y. (2017) · Drugs of today · doi:10.1358/dot.2017.53.11.2725754 · Cited by 91
Enhancing Poxvirus Oncolytic Effects through Increased Spread and Immune Evasion
Kirn, D. H., Wang, Y., Liang, W., Contag, C. H., & Thorne, S. H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6515 · Cited by 89
Gu, Z., Yamashiro, J. M., Kono, E. A., & Reiter, R. E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2086 · Cited by 88
Smart CARs engineered for cancer immunotherapy
Priceman, S. J., Forman, S. J., & Brown, C. E. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000232 · Cited by 71
Self-citationModulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy
Yin, J., Markert, J. M., & Leavenworth, J. W. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00136 · Cited by 57
O’Leary, M. P., Choi, A. H., Kim, S., Chaurasiya, S., Lü, J., Park, A. K., Woo, Y., Warner, S. G., Fong, Y., & Chen, N. G. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1483-x · Cited by 49
Self-citationPublisher Correction: Oncolytic viruses as engineering platforms for combination immunotherapy
Twumasi‐Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C., & Nelson, B. H. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0019-2 · Cited by 46
Chaurasiya, S., Chen, N. G., Lü, J., Martin, N. T., Shen, Y., Kim, S., Warner, S. G., Woo, Y., & Fong, Y. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0114-x · Cited by 43
Self-citationRegulating Cytokine Function Enhances Safety and Activity of Genetic Cancer Therapies
Chen, H., Sampath, P., Hou, W., & Thorne, S. H. (2013) · Molecular Therapy · doi:10.1038/mt.2012.225 · Cited by 30
Choi, A. H., O’Leary, M. P., Lü, J., Kim, S., Fong, Y., & Chen, N. G. (2018) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2018.04.001 · Cited by 26
Self-citationAxicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas
Sharma, P., King, G., Shinde, S. S., Purev, E., & Jimeno, A. (2018) · Drugs of today · doi:10.1358/dot.2018.54.3.2776625 · Cited by 16
Cited by
Navigating CAR-T cells through the solid-tumour microenvironment
Hou, A. J., Chen, L. C., & Chen, Y. Y. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00189-2 · Cited by 551
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
Oncolytic virotherapy: basic principles, recent advances and future directions
Lin, D., Shen, Y., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01407-6 · Cited by 459
CD8+ T cells in the cancer-immunity cycle
Giles, J. R., Globig, A.-M., Kaech, S. M., & Wherry, E. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.005 · Cited by 449
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Wagner, J., Wickman, E., DeRenzo, C., & Gottschalk, S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.015 · Cited by 380
Metadata
- Authors
- Park, A. K., Fong, Y., Kim, S.-I., Yang, J., Murad, J. P., Lu, J., Jeang, B., Chang, W.-C., Chen, N. G., Thomas, S. H., Forman, S. J., & Priceman, S. J.
- Venue
- Science Translational Medicine
- Published
- 2020-09-02
- Volume
- 12
- Issue
- 559
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3081669695
- Cited by
- 271
- References
- 48
- FWCI
- 10.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.